Harbor Multi asset Explorer ETF News - MAPP

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

--Trial to be used in support of NDA submission-- MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc...

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at...

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has secured a committed...

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present...

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has completed a planned...

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

-- Analysis Shows Potential of LEVADEX to Treat a Broad Spectrum of Migraine -- -- Company to Host Webcast on Monday, September 14th at 7:15 a.m...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Harbor Multi asset Explorer ETF (MAPP)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MAPP News

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

AstraZeneca Terminates MAP Pharma Pact, Sees $44 Million charge In 2Q

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

MAPP Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Harbor Multi asset Explorer ETF (MAPP) News

Harbor Multi asset Explorer ETF (MAPP)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MAPP News

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

AstraZeneca Terminates MAP Pharma Pact, Sees $44 Million charge In 2Q

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

MAPP Discussion

Your Recent History